A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

PHASE3RecruitingINTERVENTIONAL

Enrollment

350

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

May 31, 2027

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

Telitacicept

Subcutaneous injection

DRUG

Placebo

Subcutaneous injection

Trial Locations (4)

RECRUITING

Rockford site, Rockford

RECRUITING

Stafford site, Stafford

RECRUITING

Hemet site, Hemet

RECRUITING

Menifee site, Menifee

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY